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Lysosomeis elegans is the simplest animal model available to study human disease. In this
review, the worm homologues for the 58 human genes involved in lysosomal storage disorders and for 105
human genes associated with lysosomal function have been compiled. Most human genes had at least one
worm homologue. In addition, the phenotypes of 147 mutants, in which these genes have been disrupted or
knocked down, have been summarized and discussed. The phenotypic spectrum of worm models of
lysosomal storage disorders varies from lethality to none obvious, with a large variety of intermediate
phenotypes. The genetic power of C. elegans provides a means to identify genes involved in speciﬁc processes
with relative ease. The overview of potential lysosomal phenotypes presented here might be used as a
starting point for the phenotypic characterization of newly developed knock-out models or for the design of
genetic screens selecting for loss or gain of suitable knock-out model phenotypes. Screens for genes involved
in lysosomal biogenesis and function have been performed successfully resulting in the cup and glo mutants,
but screens involving subtle phenotypes are likely to be difﬁcult.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
1.1. The lysosome
In 1949, Christian De Duve discovered the cellular bodies in which
digestion occurs and called them lysosomes, since they contained
mixtures of lytic enzymes (reviewed in [1]). These organelles were
identiﬁed due to the application of different homogenization proce-
dures. Gentle homogenization allows the lysosomes to stay intact and,
therefore, facilitates retentionof theenzymatic activities inside,whereas
drastic homogenization causes disruption of the lysosomal membranes
permitting measurements of lysosomal enzyme activity. De Duve [1]
drew a parallel between the digestive tract of a multicellular organism
and the “digestive tract” of a cell, both having a resistant envelope with
multiple functions, e.g., to protect the rest of the organism or cell from
digestion, uptake and secretion of compounds, and to maintain the
degradative environment. Moreover, he reasoned that defective func-
tioning of lysosomes could possibly lead to incomplete breakdown and
subsequent accumulation of the indigestible substance, eventually
causing the cell that harbors the defective lysosomes to become
inoperative or even go into apoptosis. SinceDeDuve's original discovery,
signiﬁcant progress has been made in elucidating the processes taking
place in the lysosomes, although much is still unknown.etics, Center for Human and
RC Leiden, The Netherlands.
).
Netherlands.
l rights reserved.1.2. Lysosomes and degradation and transport
Most eukaryotic cells contain lysosomes or organelles of over-
lapping function, which exist in a variety of shapes and sizes. These
acidic degradative organelles are surrounded by a single lysosomal
membrane and have a pH of about 5, which is lower than the
cytoplasmic pH of approximately 7.2. They contain 50–60 hydrolytic
enzymes, collectively called the acid hydrolases that usually reside in
the lysosomal lumen and have optimal activities at luminal pH. In
contrast, the lysosomal membrane proteins are functional in a variety
of processes such as lysosome biogenesis, maintenance of endosomal
transport, lysosomal enzyme targeting and autophagy [2]. An
important group of lysosomal membrane proteins is the vacuolar-
type proton ATPase complexes, which pump protons into the
lysosomes to maintain the low luminal pH necessary for optimal
hydrolase activity [3]. Inward chloride channels in the lysosomal
membrane neutralize the resulting increase in positive charge [3]. At
least in mammals, most of the hydrolytic enzymes are transported to
the lysosomes via the ‘direct’ mannose-phosphate pathway, while
lysosomal membrane proteins use both the ‘direct’ pathway and the
‘indirect’ pathway via the plasmamembrane, to travel to the lysosome
[4,5]. No homologues of mannose-6-phosphate receptors have been
identiﬁed in Caenorhabditis elegans, suggesting that mannose-6-
phosphate signals for the sorting of newly synthesized lysosomal
enzymesmay have been replaced by an amino acid based signals and a
vps10/sortilin receptor system similar to that in yeast [6]. Further-
more, although the post-translational modiﬁcation pathways are con-
served, the structures of the glycoconjugates (glycolipids, O-glycans
and N-glycans) in mammals are different from those in ﬂies and
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do not have sialic acid modiﬁcations [7–9].
Lysosomes obtain their constituents and material to be degraded
through vesicular trafﬁcking. For example, transport vesicles contain-
ing hydrolytic enzymes can combine with lysosomes or vesicles ﬁlled
with endocytosed compounds called endosomes. After the endocy-
tosed materials have been degraded, lysosomal proteins can be
recycled, catabolizedmaterials can be reused as building blocks for the
anabolic processes in the cell, and waste products may be excreted
from the cell. Furthermore, similar processes of vesicular ﬁssion or
fusion, and intralysosomal degradation may occur with autophago-
somes in order to recycle old or obsolete organelles or other parts of
the cell.
1.3. Lysosomal storage diseases
When any process discussed above is not working properly, this
may lead to partly or completely dysfunctional lysosomes that are
unable to degrade speciﬁc compounds causing their accumulation
(see [10] for a detailed description of lysosomal storage diseases). The
mass of stored materials can cause the lysosomes to become inﬂexible
or enlarged cellular compartments that are disrupting other processes
taking place in the cell, thus leading to a lysosomal storage disorder.
Most of the lysosomal storage diseases are caused by defects in
hydrolytic enzymes, such as the acid α-glucosidase deﬁciency in the
ﬁrst described lysosomal storage disorder, Pompe disease
(MIM232300) [11]. Acid α-glucosidase deﬁciency causes storage of
glycogen in lysosomes of numerous tissues. In the most severe form of
this disease, patients suffer from prominent cardiomegaly, hypotonia,
and hepatomegaly and they ﬁnally die due to cardiorespiratory failure,
usually before the age of two [12].
In addition to enzyme deﬁciencies, disturbed protein sorting or
vesicular trafﬁcking may also lead to lysosomal storage disorders,
e.g., in Mucolipidosis type II or I-cell disease (MIM252500). Cells
of mesenchymal origin from I-cell disease patients have reduced
N-acetylglucosamine-1-phosphotransferase activity in the Golgi appa-
ratus and fail to add anN-acetylglucosamine-1-phosphate group to the
mannose residues already present on the lysosomal enzyme precursors
[13]. Lysosomal enzymes lacking proper modiﬁcation are secreted
instead of normally transported to the lysosomes. Affected cells contain
dense inclusions of storage material, hence the name inclusion cell or
I-cell disease. I-cell disease patients generally suffer from severe
progressive psychomotor retardation and premature death in the ﬁrst
decade of life.
The severe pathologies of some lysosomal storage disorders have
prompted research into the etiology of the more than 40 known
lysosomal storage diseases [14,15]. Formost diseases causativemutations
have been described and possible treatments are being developed. For
instance, enzyme replacement therapy provides treatment of Gaucher's
disease, in which the gene encoding the enzyme acid β-glucosidase is
mutated [16]. For most lysosomal storage diseases only symptomatic
treatment of the patients is possible at the moment. Although much is
knownconcerning lysosomal processes and themechanisms required for
a lysosome to be functional, some questions remain unanswered:
whether and how undigested accumulated materials cause the symp-
toms observed in patients suffering from lysosomal storage diseases or
whether the accumulation is a primary or merely a side effect and why
only certain cell types are affected [17].
1.4. Prerequisites of lysosomal disease models and C. elegans
To investigate the mechanisms underlying lysosomal storage
disorders and their relation with the disease phenotype, appropriate
model organisms are required. These organisms preferably should be
eukaryotic, multicellular organisms, but straightforward to use and
genetically easily modiﬁable. Furthermore, a fully sequenced genomewould help to identify homologous genes and well-characterized
developmental pathways would facilitate the study of mutant
phenotypes. This proﬁle is matched by the mouse, the ﬂy Drosophila
melanogaster and the less complex nematode C. elegans, which was
initially described by Sydney Brenner [18]. The nematode is a
convenient and nowadays widely used model organism with a 3-
day generation time and an entirely known cell lineage. These worms
exist in two sexes: hermaphrodites that easily self-fertilize to obtain
homozygous mutants and males that can be used to perform crosses.
Moreover, since neurological symptoms are common in human
lysosomal storage diseases, the very well-characterized and invariably
wired nervous system of C. elegans might be an advantage. The
hermaphrodite has 302 neurons on a total of 959 cells. The worm is
amenable to large genetic screens and a comprehensive toolset for
worm research on a genetic, cellular, and behavioral level is available.
Gene speciﬁc loss-of-function mutations can easily be phenocopied
using RNA interference (RNAi) by microinjection, soaking or feeding
methods. Whole genome approaches have delivered a vast amount of
data, even on previously unannotated sequences, providing clues to
the function of the putative proteins [19]. In the context of lysosomal
research, it should be pointed out, however, that C. elegans genetics
has evolved much more than its cell biology and biochemistry.
1.5. Lysosomes in C. elegans
Clokey and Jacobsen [20] were the ﬁrst to hypothesize that the gut
granules, which ﬁll the intestinal cells of C. elegans, were intestine-
speciﬁc secondary lysosomes, which are formed by the fusion of a
primary lysosome and a vesicle containing material to be degraded,
such as a phagosome or pinosome. The gut granules are ﬁlled with
birefringentmaterial and easily detected in livingworms. The lysosomal
markers Acridine Orange and LysoTracker Red mainly stain the gut
granules suggesting that they are related to lysosomes. In addition,
immunostaining of homologues to known lysosomal proteins indicates
their colocalization with gut granules. The stainings also suggest that
lysosomes or lysosome-related organelles are not easily detectable with
these markers in most other cell types of wild type worms. Transgenic
wormsexpressing lysosomal protein-GFP fusionshavebeenconstructed
to determine the expression pattern of lysosomal genes [21]. The
drawback of using such transgenic worms for organelle detection is that
the fusion proteins may affect normal lysosomal function. Three popu-
lations of vesicles with different electron densities are visible in gut cells
byelectronmicroscopy [22]. Lysosomes arenot readily observed inother
cells, apart fromcoelomocytes, scavenger cells,whichuse endocytosis to
take up materials from the body cavity of the worm before lysosomal
degradation [23]. Therefore, studies on C. elegans lysosomes have
focussed on the formation of gut granules and the uptake of material by
coelomocytes, which have been regarded as equivalents of lysosomal
biogenesis and lysosomal degradation. Successful screens were per-
formed for mutants showing gut granule loss (glo) or coelomocyte
uptake defects (cup) to identify candidate genes involved in these
lysosomal processes [23,24].
Therefore, we have investigated the potential of this worm as a
model organism for lysosomal storage disorders.
We have compared all human protein sequences known to be
involved in lysosomal storage disorders with C. elegans protein
sequences using the best reciprocal Blast score to identify the putative
worm homologues of these lysosomal disease proteins. Subsequently,
we compiled all phenotypes of nematodes with mutations in the
putative homologous genes in order to get an overview of all possible
lysosomal phenotypes present in theworm. Similar comparisonswere
performed with human proteins that were involved in lysosomal
processes but that were still unassociated with disease. The homo-
logues and their phenotypes were listed, as were those of the already
known C. elegans loci involved in lysosomal function, encompassing
all possible lysosomal phenotypes that are known in C. elegans at the
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screens was studied to discuss their potential to identify modifying
mutations in genes involved in the same molecular process as the C.
elegans homologues.
1.6. C. elegans homologues to human lysosomal storage disease genes
We identiﬁed C. elegans homologues for almost all 58 human
genes associated with lysosomal storage diseases (Table 1). Thirty
three of the human genes encode lysosomal enzymes, but only 21
enzyme-encoding homologues were present in the worm. Unfortu-
nately, most enzyme activities have not been determined in relation to
speciﬁc genes due to lack of mutants or redundancy. Most of the
human disease genes have only a single homologue, except the two
involved in Niemann–Pick disease, NPC1 and SMPD1 (two and three
homologues, respectively), and the juvenile neuronal ceroid lipofus-
cinosis gene CLN3 (three homologues). Conversely, a single worm
homologue has been identiﬁed for each of three human gene pairs,
HEXA-HEXB, GLA-NAGA and GALNS-ARSA. For all 42 C. elegans
homologues, information on gene function can be found in literature
and in the Wormbase database [25]. Ten of these C. elegans genes,
which have been studied individually in the nematode, are homo-
logous to genes involved in Mucolipidosis type IV (MIM252650),
Niemann–Pick type C (MIM257220), Danon disease (MIM300257),
Hermansky–Pudlak Syndrome-2 (MIM608233) and congenital, infan-
tile, and juvenile forms of neuronal ceroid lipofuscinosis (NCL)
(MIM610127, MIM256730, and MIM204200, respectively). Data on
the other 32 genes were derived from sequence similarities or came
fromwhole genome approaches, such asmicroarray analyses [26], and
whole genome RNAi experiments [27], of which the details are listed
in Wormbase. After RNAi knockdown of 35 genes, worm phenotypes
ranged from none (26 times) to (embryonic) lethality (twice) with
seven subtle intermediary phenotypes (Table 1). Although mutants
have been isolated for 19 of the genes, 7 out of the 11 mutants
characterized had a mainly subtle phenotype. The available informa-
tion about nematode homologues to human lysosomal storage disease
genes is summarized below in order to get an overview of all possible
phenotypes of worm models for lysosomal storage disorders.
1.6.1. C. elegans cup-5, homologous to the Mucolipidosis type IV gene
MCOLN1, and lysosome biogenesis
Mucolipidosis type IV, caused by mutations in theMCOLN1 gene, is
a neurodegenerative lysosomal storage disorder of which the main
symptoms are psychomotor retardation and ophthalmologic abnorm-
alities [28–30]. Ultrastructural analysis of patient tissues usually
reveals many enlarged vacuoles, presumably lysosomes in which
lipids are stored as well as water-soluble granulated substances. The
MCOLN1 gene encodes the lysosomal membrane protein h-mucoli-
pin-1, which has six predicted transmembrane domains and functions
as a non-selective cation channel of which the activity is modulated by
pH [31]. The C. elegans MCOLN1 homologue cup-5 is a functional
orthologue of the human MCOLN1 gene, since the coelomocyte up-
take (Cup) phenotype of cup-5 mutants, consisting of heterogeneous
enlarged vacuoles and embryonic lethality, can be rescued by
expressing the human gene in these mutants [32]. Mutations in the
cup-5 gene were identiﬁed by screening for mutants with disrupted
endocytosis [33], and in mutants with affected programmed cell death
[32]. The cup-5 gene is expressed in most tissues in adult worms, and
subcellularly localized to nascent and mature lysosomes [34]. Similar
to patient cells, cells from cup-5 mutants have enlarged vacuoles and
lysosomes, apparently due to defective lysosomal degradation
processes. The CUP-5 proteinwas suggested to play a role in lysosome
biogenesis or maturation [34], because h-mucolipin-1 was shown to
be a Ca2+-permeable channel [35], and Ca2+ transport is essential for
fusion of late endosomes and lysosomes and for reformation of
lysosomes [36]. Interestingly, through a screen for modiﬁer alleles, amutation in the mrp-4 gene, encoding an endosomal–lysosomal ABC
transporter, was shown to suppress cup-5 lethality and rescue the
lysosomal degradation and developmental defects of the cup-5
mutants [37]. In the cup-5 mutants, degradation of the ABC
transporter was delayed, causing an imbalance in the endosomal–
lysosomal import of compounds, which probably interferes with
normal degradation processes. The affected degradation is thought to
lead to starvation of the cells and independently to developmental
defects. Absence of the ABC transporter results in rescue of lysosomal
function, thereby permitting the cells to survive. Whether similar
events contribute to the cellular and neuronal degeneration in
Mucolipidosis type IV patients is still unknown, but if this is the
case reducing the activity of ABC transporters might provide for a
therapy for the treatment of Mucolipidosis type IV.
1.6.2. Nematode Niemann–Pick type C homologues involved in
cholesterol trafﬁcking
Multiple forms of Niemann–Pick disease exist, either caused by
deﬁcient acid sphingomyelinase activity leading to accumulation of
sphingomyelin in Niemann–Pick types A and B [38,39], or by defective
cholesterol trafﬁcking resulting in lysosomal storage of unesteriﬁed
cholesterol in Niemann–Pick type C [40]. Symptoms caused by acid
sphingomyelinase deﬁciency vary from hepatosplenomegaly and
progressive neurodegenerative disease to pulmonary inﬁltration.
Patients suffering from defective cholesterol trafﬁcking also display
progressive neurological disease and possibly prominent hepatic dam-
age. Three acid sphingomyelinase (ASM) homologues were identiﬁed in
C. elegans, while in other organisms only one ASM could be identiﬁed
[41]. Unfortunately, according to the Wormbase database, mutants for
only one of the C. elegans ASM homologues are available, but their
phenotypes were not described. No ASM RNAi phenotypes emerged
from genome-wide RNAi screens [25], but RNAi targeted against
multiple ASM genes perhaps could result in an interesting knock-
down phenotype and provide a model for Niemann–Pick types A and B.
Niemann–Pick type C can be caused by mutations in two genes,
NPC1 and NPC2, encoding proteins with NPC and sterol sensing
domains that are implicated in retrograde transport from sterols and
other cargo from lysosomes [40,42,43]. Each has one worm homo-
logue, ncr-1 and ncr-2, respectively [36]. Worms without ncr-1 are
hypersensitive to lack of cholesterol, an essential substance for the
nematode, and to exposure to progesterone, which can inhibit
intracellular cholesterol trafﬁcking in mammalian cells [44,45]. In
contrast, ncr-2 single mutants appear superﬁcially wild type. Whereas
ncr-2; ncr-1 double mutants display constitutive inappropriate dauer
formation, which could be rescued bymicroinjection of NCR-2 or NCR-
1 wildtype genes, suggesting both proteins play redundant roles to
prevent dauer formation under favorable conditions. The dauer is a
relatively stress-resistant alternative larval life stage that the animal
can form when it develops under stressful conditions. Furthermore,
ncr-2; ncr-1 double mutants have abnormal morphology of certain
neurons during transient dauer stage. Other ncr-2; ncr-1 double
mutant phenotypes encompass developmental pleiotropic pheno-
types similar to daf-9 and daf-12 mutants including reproductive
defects, concordant reduced brood size and life span, vulval
abnormalities and disruption of the cuticular alae. Epistasis analysis
placed NCR-1 and NCR-2 upstream of DAF-9 in the dauer formation
pathway [44,45]. Therefore, the NCR-1 and NCR-2 proteins that were
suggested to play a role in intracellular cholesterol trafﬁcking may
provide the substrate for DAF-9, the ER localized cytochrome P450
enzyme, which catalyzes a reaction to form a lipophilic hormone for
the DAF-12 nuclear receptor [46,47]. Under cholesterol-deprived
conditions, ncr-2; ncr-1 double mutant worms could be unable to
efﬁciently transport this hormone progenitor to the site of DAF-9
action and hence stimulate dauer formation due to absence of the
signal to bypass the dauer stage. Further examination of how the
mutations in NCR-1 and NCR-2 lead to the other phenotypes, and,
Table 1
Human lysosomal storage disorder genes and their C. elegans homologues
Lysosomal storage disorder Human
gene
MIM
numbera
C. elegans
homologue
% Similarity
to human
gene
Function of human protein C. elegans
mutantc
RNAi and phenotypese
Neuronal ceroid lipofuscinoses (NCL)
Infantile NCL PPT1
(CLN1)
600722 F44C4.5 54 Palmitoyl-protein thioesterase 1 precursor
(EC 3.1.2.22)
ppt-1 M: delayed egg-laying, abnormal
mitochondria; R: none observed
(Congenital ovine NCL) CTSD 116840 R12H7.2b 61 Cathepsin D precursor (EC 3.4.23.5) asp-4d) R: Ced
Late infantile NCL TPP1
(CLN2)
204500 None Tripeptidyl-peptidase 1 precursor (EC 3.4.14.9)
Juvenile NCL CLN3 204200 F07B10.1 53 Unknown cln-3.1 M: slightly reduced life span;
R: none observed
C01G8.2 49 cln-3.2 M: slightly reduced brood size;
R: none observed
ZC190.1 62 cln-3.3 R: none observed
Late infantile NCL,
Finnish variant
CLN5 256731 None Unknown
Late infantile NCL,
Indian variant
CLN6 601780 None Unknown
Northern epilepsy CLN8 600143 None Unknown
Oligosaccharidoses
Alpha-mannosidosis MAN2B1 248500 F55D10.1 52 Lysosomal alpha-mannosidase precursor
(EC 3.2.1.24)
R: none observed
Beta-mannosidosis MANBA 248510 C33G3.4 53 Beta-mannosidase precursor (EC 3.2.1.25) R: none observed
Fucosidosis FUCA1 230000 W03G11.3 50 Tissue alpha-L-fucosidase precursor
(EC 3.2.1.51)
R: none observed
Farber's disease ASAH1 228000 K11D2.2 62 Acid ceramidase precursor (EC 3.5.1.23) asah-1d) R: age, Reduced lifespan
Aspartylglucosaminuria AGA 208400 R04B3.2 56 N(4)-(beta-N-acetylglucosaminyl)-l-
asparaginase precursor (EC 3.5.1.26)
R: none observed
Galactosialidosis PPGB 256540 F41C3.5 59 Lysosomal protective protein precursor
(EC 3.4.16.5)
R: none observed
Sphingolipidoses
Tay–Sachs disease, GM2
gangliosidosis I
HEXA 272800 T14F9.3 56 Beta-hexosaminidase alpha chain precursor
(EC 3.2.1.52)
hex-1 M: no chitotriosidase activity,
reduced hexosaminidase activity;
R: none observedSandhoff disease, GM2
gangliosidosis II
HEXB 268800 T14F9.3 55 Beta-hexosaminidase beta chain precursor
(EC 3.2.1.52)
hex-1
GM2-gangliosidosis type ab GM2A 272750 None Ganglioside GM2 activator precursor
Krabbe disease GALC 245200 C29E4.10 31 Galactocerebrosidase precursor (EC 3.2.1.46) R: none observed
Gaucher disease GBA 606463 F11E6.1 42 Glucosylceramidase precursor (EC 3.2.1.45) R: none observed
Variant metachromatic
leukodystrophy
PSAP 176801 C28C12.7 21 Proactivator polypeptide precursor, prosaposin spp-10 M, R: none observed
Variant Gaucher disease PSAP 176801 C28C12.7 21 Proactivator polypeptide precursor, prosaposin spp-10
Variant Tay–Sachs disease
(gm2-gangliosidosis)
PSAP 176801 C28C12.7 21 Proactivator polypeptide precursor, prosaposin spp-10
Niemann–Pick disease A and B SMPD1 257200 ZK455.4 55 Sphingomyelin phosphodiesterase precursor
(EC 3.1.4.12)
asm-2d) R: none observed
W03G1.7 53 asm-3 M: ND; R: none observed
B0252.2 52 asm-1d) R: none observed
Niemann–Pick disease C1 NPC1 257220 F09G8.4 47 Niemann–Pick C1 protein precursor ncr-2
(npc-2)
M: hypersensitive to cholesterol
deprivation, hyperactive egg layer,
slow development, inappropriate
dauer forming; R: Emb
F02E8.6 46 ncr-1
(npc-1)
M: hypersensitive to cholesterol
deprivation, hyperactive egg layer,
slow development, inappropriate
dauer forming; R: none observed
Fabry's disease,
sphingolipidosis
GLA 301500 R07B7.11 54 Alpha-galactosidase A precursor
(EC 3.2.1.22)
gana-1d) R: reduced enzyme activity
Schindler disease NAGA 104170 R07B7.11 53 Alpha-N-acetylgalactosaminidase
precursor (EC 3.2.1.49)
gana-1d) R: reduced enzyme activity
Mucopolysaccharidoses
Mucopolysaccharidosis
type I, Hurler/Scheie syndrome
IDUA 252800 None Alpha-l-iduronidase precursor (EC 3.2.1.76)
Mucopolysaccharidosis
type II, Hunter syndrome
IDS 309900 None Iduronate 2-sulfatase precursor (EC 3.1.6.13)
Mucopolysaccharidosis type IIIA,
Sanﬁlippo disease IIIA
SGSH 252900 F26H9.1 35 N-sulphoglucosamine sulphohydrolase
precursor (EC 3.10.1.1)
chis-1 M: ND, R: none observed
Mucopolysaccharidosis type IIIB,
Sanﬁlippo disease IIIB
NAGLU 252920 K09E4.4 42 Alpha-N-acetylglucosaminidase precursor
(EC 3.2.1.50)
R: none observed
Mucopolysaccharidosis type IIIB,
Sanﬁlippo disease IIIC
HGSNAT 252930 None Heparan-alpha-glucosaminide
N-acetyltransferase (E.C. 2.3.1.78)
Mucopolysaccharidosis type IIID,
Sanﬁlippo disease IIID
GNS 252940 K09C4.8 40 N-acetylglucosamine-6-sulfatase precursor
(EC 3.1.6.14)
sul-1 M, R: none observed
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Table 1 (continued)
Lysosomal storage disorder Human
gene
MIM
numbera
C. elegans
homologue
% Similarity
to human
gene
Function of human protein C. elegans
mutantc
RNAi and phenotypese
Mucopolysaccharidoses
Mucopolysaccharidosis type
IVB, Morquio syndrome B
GLB1 230500 T19B10.3 41 Beta-galactosidase
precursor (EC 3.2.1.23)
R: none observed
Mucopolysaccharidosis type
IVA, Morquio syndrome A
GALNS 253000 D1014.1 41 N-acetylgalactosamine-6-sulfatase
precursor (EC 3.1.6.4)
sul-2 M, R: none observed
Metachromatic leucodystrophy ARSA 250100 D1014.1 40 Arylsulfatase A precursor (EC 3.1.6.8) sul-2
Mucopolysaccharidosis type VI,
Maroteaux-Lamy
ARSB 253200 C54D2.4 33 Arylsulfatase B precursor (EC 3.1.6.12) sul-3 d R: none observed
Mucopolysaccharidosis type VII,
Sly syndrome
GUSB 253220 Y105E8B.9 39 Beta-glucuronidase precursor (EC 3.2.1.31) R: none observed
Hyaluronidase deﬁciency
(Mucopolysaccharidosis type IX)
HYAL1 601492 T22C8.2 31 Hyaluronidase-1 precursor (EC 3.2.1.35) R: none observed
Lysosomal transporter defects
Nephropathic cystinosis CTNS 606272 C41C4.7 48 Cystinosin ctns-1 M: ND, R: none observed
Infantile sialic acid storage
disorder(ISSD) and Salla disease
SLC17A5 604322 C38C10.2 60 Sodium/sialic acid cotransporter, sialin R: none observed
Lysosomal Lysosomal-trafﬁcking defects
Mucolipidosis, type IV MCOLN1 605248 R13A5.1 55 Mucolipin-1 cup-5 M: maternal-effect embryonic
lethal; R: none observed
Hermansky–Pudlak syndrome HPS1 604982 None Biogenesis of lysosome-related
organelles complex 3 component
AP3B1
(HPS2)
603401 R11A5.1 56 AP-3 complex subunit beta-1 apb-3
(apt-6)
M: ND; R: Emb, Let, Lva, Dpy,
fat content reduced
HPS3 606118 None Biogenesis of lysosome-related
organelles complex 2 component
HPS4 606682 None Biogenesis of lysosome-related
organelles complex 3 component
HPS5 607521 W09G3.6 27 Biogenesis of lysosome-related
organelles complex 2 component
R: fat content reduced
HPS6 607522 None Biogenesis of lysosome-related
organelles complex 2 component
DTNBP1
(HPS7)
607145 None Dystrobrevin-binding protein
1 (Dysbindin), BLOC1 subunit
BLOC1S3
(HPS8)
609762 None Biogenesis of lysosome-related
organelles complex-1 subunit 3
VPS33A 610034 B0303.9 25 Vacuolar protein sorting 33A slp-1 M: ND, R: none observed
Mucolipidosis, types II and IIIA GNPTAB 607840 None N-acetylglucosamine-1-phosphotransferase
subunits alpha/beta precursor (EC 2.7.8.17)
Mucolipidosis, type IIIC GNPTG 607838 ZK1307.8 38 N-acetylglucosamine-1-phosphotransferase
subunit gamma precursor (EC 2.7.8.17)
? M: ND, R: none observed
Others
Glycogen storage disease type II,
Pompe disease
GAA 232300 D2096.3 37 Lysosomal alpha-glucosidase
precursor (EC 3.2.1.20)
? M, R: ND
Chediak–Higashi syndrome LYST
(CHS1)
214500 VT23B5.2 32 Lysosomal-trafﬁcking regulator ? M: ND, R: none observed
F10F2.1 34 R: response to contact abnormal
Wolman disease/cholesteryl
ester storage disease
LIPA 278000 R11G11.14 59 Lysosomal acid lipase/cholesteryl ester
hydrolase precursor (EC 3.1.1.13)
R: Him, fat content reduced
Glycogen storage disease type
Iib, Danon disease
LAMP2 300257 C03B1.12 25 Lysosome-associated membrane
glycoprotein 2 precursor
lmp-1 M: gut lighter, one type of
intestinal granule missing; R:Clr
Sialidosis NEU1 256550 None Sialidase-1 precursor (EC 3.2.1.18)
Multiple sulfatase deﬁciency SUMF1 272200 None Sulfatase-modifying factor 1 precursor
Lipoid proteinosis of Urbach
and Wiethe
ECM1 602201 None Extracellular matrix protein 1 precursor
Dyggve–Melchior–Clausen
dysplasia/Smith–McCort dysplasia
DYM 607461 C47D12.2 96 Dymeclin R: Emb, Let, Muv
Cathepsin E deﬁciency CTSE 116890 R12H7.2b 59 Cathepsin E precursor (EC 3.4.23.34) asp-4d R: Ced
a Online Mendelian Inheritance in Man (http://www.ncbi.nlm.nih.gov/Omim/searchomim.html).
b Due to high similarity between cathepsin homologues, the highest unidirectional man-worm hit is shown.
c ? Deletion mutant, gene name unknown. Old gene designations are shown between parentheses.
d Gene name assigned, but no mutant available.
e M:Mutant, R: RNAi, ND: not determined; Phenotype abbreviations: Age: life span abnormal; Ced: cell death abnormal; Clr: clear; Dpy: dumpy; Emb: embryonal lethal; Him: high
incidence of males; Let: lethal; Lva: larval arrest; Lvl: larval lethal; Muv: multi-vulva.
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other functional aspects of these proteins.
1.6.3. C. elegans LMP-1 protein, homologous to the Danon disease protein
LAMP2, involved in lysosome biogenesis
Mutations in the lysosome-associated membrane protein-2 gene
(LAMP2) cause glycogen storage disease type IIb or Danon disease,characterized by cardiomyopathy, myopathy and variable mental
retardation [48]. Originally, Danon disease was described as a variant
glycogen storage disease type II, since acid-maltase or alpha-
glucosidase activity was normal [49]. LAMP2 and structurally similar
LAMP1 are heavily glycosylated lysosomal membrane proteins with
one transmembrane domain and a major intralysosomal part, and are
thought to be functional in lysosome stability and integrity [2]. LAMP-
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LAMP protein function [50,51]. LAMP-2 knock-out mice suffered from
cardiomyopathy and accumulation of autophagic vacuoles, similar to
human Danon disease patients. LAMP-1 knock-out mice displayed no
overt phenotype but overexpressed LAMP-2, suggesting functional
redundancy. Additional functional and morphological studies of the
heart of LAMP-2 knock-out mice showed that these mice suffered
from contractile dysfunction that was suggested to be due to
morphological changes [52]. Embryonic ﬁbroblasts from LAMP-1
LAMP-2 double knock-out mice show impaired motility and fusion
of lysosomes to phagosomes, which suggests that the LAMP proteins
are involved in lysosomal fusion to phagosomes and may explain the
accumulation of autophagic vacuoles [53]. Kostich et al. [22] have
searched the C. elegans genome for LAMP-like sequences and
identiﬁed a LAMP homologue lmp-1, which has a lysosomal targeting
sequence (GYXXΦ, in which Φ is a large hydrophobic amino acid
residue and X is an unspeciﬁed amino acid) at its COOH terminus. Our
BLAST search with the human LAMP2 protein sequence against the
C. elegans protein database Wormpep [25] resulted in the highest hit,
with LMP-1 and a lower score with LMP-2, which has no GYXXΦ
motif. Nematode lmp-1 deletion mutants are viable and fertile, show
alternative intestinal granule populations, and apparent loss of one
type of granule, hence LMP-1 is likely to be functional in lysosome
biogenesis or maintenance [22]. How loss of the lmp-1 gene causes
this change in granule composition and whether the irregular
granules reminiscent of granule fusion or engulfment indicate that
autophagy is affected in these mutants remains to be elucidated. If
lmp-1 gut granule loss can be scored under a standard Differential
Interference Contrast (DIC) microscope, screening for mutations that
resemble or modify the Lmp-1 phenotype could be feasible [54].
1.6.4. Hermansky–Pudlak syndrome type 2 (HPS type 2) and the APβ3a
homologue in the worm implicated in development
The heterogenous group of diseases collectively known as Her-
mansky–Pudlak syndrome (HPS) is pathologically characterized by
prolonged bleeding, albinism and lysosomal storage of ceroid, and
presumably results fromdefects inmultiple cytoplasmic organelles, such
asmelanosomes, platelet-densegranules, and lysosomes [55].Mutations
in eight genes,HPS1 –HPS8, have been shown to cause this disorder and
the proteins encoded by these genes are thought to be involved in the
biogenesis or transport of lysosomes or lysosome-related organelles
[56,57]. The HPS-1 and HPS-4 proteins appear to form a complex that
might play a role in the biogenesis of lysosomes [58,59]. These proteins
were suggested to function independently from the Adaptor Protein 3
(AP-3) complex, which is involved in formation of carrier vesicles and
cargo recruitment for protein transport. We could not identify C. elegans
sequences homologous to HPS-1, HPS-3, HPS-4, and HPS-6 by mere
protein sequence comparison, suggesting that these proteins are simply
not present in the nematode or their sequences have diverged beyond
recognition. HPS-5, HPS-7 and HPS-8 have putative nematode homo-
logues, but these have not yet been investigated individually and the
high throughput approaches did not elucidate any functional aspects of
these proteins [25]. HPS type 2 is caused by mutations in the gene
encoding the β3a subunit of the AP-3 complex [60]. AP-3 is involved in
the sorting of transmembrane proteins from endosomes and the trans-
Golgi network to lysosomes and endosome–lysosome-related orga-
nelles, but it is unknown how altered AP-3 function leads to HPS type 2
[61,62]. The C. elegans homologue for this protein, Apb-3, appears to be
required for development as RNAi knockdown of the apb-3 transcript
causes embryonic and larval lethality [63]. Interestingly, worm knock-
outs for two other AP-3 complex subunits, apt-6 and apt-7, encoding β3
and μ3 subunits respectively, have an embryonic gut granule loss (Glo)
phenotype and larvae and adult mutant worms have less autoﬂuor-
escent gut granules [24]. The autoﬂuorescent gut granules are presumed
to be secondary lysosomes that may contain yolk or other nutrients
[20,22]. Loss of gut granules due to affected Apb-3 functionmay indicatea reduced capacity to degrade materials taken up by endocytosis or
phagocytosis to nutrients, leading to the nutrient deprivation and
subsequent lethality observed in apb-3 RNAi worms. Additional
investigations, such as genetic screens for alleles modifying the larval
arrest or the Glo phenotypes, could provide further insight into AP-3
dependent processes and the precise role of AP-3 in protein trafﬁcking.
1.6.5. Neuronal ceroid lipofuscinoses (NCL) and the worm asp-4, ppt-1
and cln-3 homologues
The congenital, infantile and juvenile forms of NCL are caused by
mutations in the CTSD, PPT1 and CLN3 genes respectively, which all lead
to severe neurodegenerative disorders with similar disease progression
but with different age of onset [64–66]. Initial symptoms include visual
deterioration followed by epileptic seizures, progressing to a state of
dementia and ending in premature death [15]. In addition to the
differences between theageof onset and the genes affected, theNCLs can
also be distinguished by the typical patterns of the lipopigment
accumulations found in lysosomes of neurons and other cell types [67].
No direct links have been established between the causative mutations,
the observed pathology and the accumulated material. The most severe
form of the NCLs, congenital neuronal ceroid lipofuscinosis, is very rare
and thus far only 10 patients have been described [64]. Patients suffering
from this disease aremicrocephalic,mayhave seizures anddie soon after
birth. This disease is caused by mutations in the CTSD gene encoding
cathepsinD and strongly resembles the congenital ovineneuronal ceroid
lipofuscinosis previously identiﬁed in sheep [68]. The nematode
homologue of the CTSD gene asp-4 is also the closest homologue of the
humanCTSE gene,which ismutated in CTSE deﬁciency, a disease distinct
from NCL [69]. Asp-4 was shown to be involved in necrotic cell death as
asp-4RNAi knockdown leads to decreased cell death, signifying its role as
an executioner protease [70]. Thus, altered cell death may underlie the
etiology of congenital neuronal ceroid lipofuscinosis.
PPT1 encodes the lysosomal enzyme palmitoyl protein thioester-
ase-1, which cleaves thioester linkages in S-acylated (palmitoylated)
proteins and facilitates the removal of the palmitate residues [71]. In
neurons however, PPT1 is also found in non-lysosomal compartments,
synaptic vesicles and synaptosomes [72]. The C. elegans CLN1
homologue is designated as ppt-1 and worms mutated in their ppt-1
gene display mitochondrial abnormalities at an ultrastructural level,
and an incompletely penetrant reproductive phenotype, so-called
‘bagging’ where eggs hatch inside the parent [73]. The juvenile NCL
gene CLN3 encodes a transmembrane protein, which is thought to be
primarily localized to lysosomes and may be implicated in pH
regulation or amino acid transport [67]. The nematode has three
homologous genes, cln-3.1, cln-3.2, and cln-3.3, which when mutated
and combined into one triple mutant strain causes a mild decrease in
life span and brood size [74]. The phenotypes of the ppt-1 and cln-3
mutants are not very suitable for genetic screens without additional
enhancement of the phenotypes. This might be accomplished by
adding compounds interfering with lysosomal acidiﬁcation. Although
the latter may not be very speciﬁc, it might be sufﬁcient to tip the
balance in favor of the more robust phenotype without increasing its
frequency in the wildtype population.
1.7. C. elegans homologues to human genes associated with lysosomal
function involved in other disorders
Not all mutations in genes associated with lysosomal function
cause lysosomal storage disease. The reason may be that these genes
encode proteins, which are localized in lysosomes or lysosome-related
organelles in certain cell types but at a different location in others. The
known mutations in these genes may impair the non-lysosomal
function of the proteins more than the lysosomal one. We have
compiled a list of thirteen disease genes encoding proteins without
clear lysosomal localization in the most affected cell types or organs
and their worm homologues (Table 2). Three of these genes, CTSC,
Table 2
C. elegans homologues to human genes associated with lysosomal function involved in disorders without known lysosomal storage
Human disorders without lysosomal
storage caused by lysosomal
protein defects
Human
gene
MIM
numbera
C. elegans
homologue
% Similarity to
human gene
Function/name C. elegans
mutantb
RNAi and mutant phenotypesc
Renal tubular acidosis with deafness ATP6V1B2 606939 F20B6.2 92 ATPase, H+ transporting,
lysosomal 56/58 kDa
V1 subunit B1
vha-12 M: ND; R: Ste Emb Let Adl Lvl
Lva Prl Locomotion abnormal
Y110A7A.12 87 spe-5? M: defective spermatogenesis;
R: Emb Let Lvl Lva Adl Prl
Locomotion abnormal
Maternal sterile
Renal tubular acidosis with deafness ATP6V1B1 192132 F20B6.2 92 ATPase, H+ transporting,
lysosomal 56/58 kDa
V1 subunit B2
vha-12
Y110A7A.12 87 spe-5?
Renal tubular acidosis, type I ATP6V0A4 605239 F35H10.4 61 Vacuolar H+-ATPase
V0 sector, subunit a
vha-5 M: homozygous lethal; R: Emb Let
Lvl Lva Gro Prl Pvl Clr Bmd Sck
Locomotion abnormal
Pyknodysostosis CTSK 601105 T03E6.7 60 Cysteine proteinase Cathepsin K cpl-1 M: ND; R: Gro Emb Let
Locomotion abnormal
Haim–Munk syndrome CTSC 602365 T10H4.12d 52 Cysteine proteinase Cathepsin C cpr-3 M: ND; R: Emb
Papillon–Lefevre syndrome CTSC 602365
Juvenile periodontitis CTSC 602365
Myeloperoxidase deﬁciency MPO 606989 ZK994.3d 55 Peroxidase catalyzing hypochlorous
acid production
pxn-1 M:ND; R: none observed
Infantile malignant autosomal
recessive osteopetrosis
TCIRG1
(OC116,
TIRC7)
604592 ZK637.8d 57 ATPase, H+ transporting, lysosomal,
V0 subunit A3
unc-32 M: severe coiler;
R: Emb Let Gro Sck
Locomotion abnormal
Maternal sterile Pvl
Infantile malignant autosomal
recessive osteopetrosis
CLCN7 602727 R07B7.1 91 Chloride channel 7 clh-6 M:ND; R: none observed
Autosomal dominant osteopetrosis CLCN7 602727 R07B7.1 91 clh-6
Infantile malignant autosomal
recessive osteopetrosis
OSTM1 607649 F42A8.3 76 Osteopetrosis-associated
transmembrane protein 1
? M:ND; R: none observed
Lowe syndrome OCRL 309000 C16C2.3 86 phosphatidylinositol
4,5-bisphosphate-5-phosphatase
ocrl-1e) R: none observed
Corneal ﬂeck dystrophy PIP5K3 609414 VF11C1L.1 66 phosphatidylinositol
4-phosphate 5-kinase
ppk-3 M: Ste, Emb, enlarged lysosomes;
R: none observed
Chorea acanthocytosis VPS13A 605978 T08G11.1 95 Vacuolar protein sorting 13A R: none observed
Arthrogryposis, renal dysfunction
and cholestasis
VPS33B 608552 C56C10.1 46 Vacuolar protein sorting 33B R: none observed
a Online Mendelian Inheritance in Man (http://www.ncbi.nlm.nih.gov/Omim/searchomim.html).
b ? Deletion mutant, gene name unknown.
c M: Mutant, R: RNAi, ND: not determined; Phenotype abbreviations: Adl: Adult lethal; Bmd: organism morphology abnormal; Clr: clear; Emb: embryonal lethal; Gro: slow
growth; Let: lethal; Lva: larval arrest; Lvl: larval lethal; Prl: paralyzed; Sck: sick; Ste: sterile.
d Multiple hits with human protein. No reciprocal best hit due to higher similarity of worm protein to a different human protein. One-directional hit with highest similarity shown.
e Gene name assigned, but no mutant available.
439G. de Voer et al. / Biochimica et Biophysica Acta 1782 (2008) 433–446MPO and TCIRG1 belong to gene families with multiple homologues in
the worm. Remarkably, most of these genes seem to be associated with
defects in polarized cells, such as renal tubular cells in renal acidosis or
osteoclasts in osteopetrosis. About half of their proteins are localized in
the plasma membrane. Many are subunits of the conserved vacuolar
ATPase pumping protons through the plasma, lysosomal and other
organellar membranes, but CLCN7 is a channel for chloride ions
compensating the positive charges of the protons in vesicles. Several
proteins are hydrolytic enzymes, such as CTSC and CTSK, involved in
degradation processes in lysosome-related organelles. One of these
processes is bone resorption, which is performed by specialized cells
called osteoclasts [75]. On contact with bone, part of their membrane
can form a rufﬂed border and create a resorptive pit, which is acidiﬁed
and ﬁlled with hydrolytic enzymes by lysosomes to degrade bone.
Defects in the acidiﬁcation or the hydrolytic enzymes can prevent bone
resorption leading to osteopetrosis. Bone defects similar to those in
osteopetrosis have been observed in mucopolysaccharidosis type VII
and have also been attributed to malfunctioning osteoclasts [76]. Thus,
with the environment of the resorptive pit resembling that of a
lysosome, one might look at osteopetrosis as a kind of extracellular
lysosomal disorder. The four remaining genes, OCRL1, PIP5K3, VPS13A,
and VPS33B play a role in lysosomal protein trafﬁcking and lysosomalmaturation. Mutant and/or RNAi knock-down phenotypes have been
determined for all 13 genes, but no obvious lysosomal phenotype was
observed apart from the enlarged lysosomes in mutants of the worm
PIP5K3 homologue, ppk-3, with their lysosomal maturation defect [77].
Although nomutations leading to lysosomal storage has been identiﬁed
yet, the human genes listed in Table 2 could be regarded as candidate
genes for lysosomal storage disorders, since knock-outmousemodels of
CLCN7 and OSTM1 display lysosomal storage and neurodegeneration in
addition to osteopetrosis [78,79].
1.8. C. elegans homologues to human genes involved in lysosomal
functioning
To complement the collection of potential lysosomal phenotypes of
the worm, we have generated a list of 92 human lysosomal genes not
yet implicated in disease and searched for their worm homologues
(Table 3).
At least one worm homologue was found for each of the 84 human
lysosomal genes. In some cases, for example vacuolar ATPase subunit
genes, the sameworm homologuewas found for several human genes
or vice versa, indicating that these genes have been duplicated or lost
in one organism compared to the other. In ﬁve other cases, a human
Table 3
Human genes encoding lysosomal proteins or proteins involved in lysosomal function unassociated with disease
Human
gene
Protein MIM
number
C. elegans
homologue
% Similarity
to human
gene
Mutant/CGC
namea
RNAi and mutant phenotypesb KO or
spontaneous
mouse mutants
ABCA2 ATP binding cassette transporter 2 600047 Y39D8C.1 53 abt-4 M, R: none observed
ABCA3 ATP binding cassette transporter 3 601615 Y39D8C.1 54 abt-4 M, R: none observed
ABCA5 ATP binding cassette transporter 5 Y39D8C.1 45 abt-4 M, R: none observed
ABCB9 ATP binding cassette transporter B9 605453 W04C9.1 41 haf-4 M: Glo; R: Emb Gro Let
F43E2.4 40 haf-2 M, R: none observed
ACP2 Lysosomal acid phosphatase 2 171650 T13B5.3 33 R: none observed nax, acp2 null
B0361.7 32 R: none observed
F52E1.8 32 R: none observed
ACP5 Acid phosphatase 5 171640 F02E9.7 36 R: none observed
ACPT Acid phosphatase, testicular 606362 B0361.7 34 R: none observed
F52E1.8 32 R: none observed
T21B6.2 32 R: none observed
ACPP Acid phospatase, prostate 171790 T13B5.3 32 R: none observed
R13H4.3 50 R: none observed
AP3B2 AP-3 adaptor complex, subunit Beta 2 602166 R11A5.1 69 apb-3 M: ND; R: Emb, Let, Lva, Dpy,
fat content reduced
AP3D1 AP-3 adaptor complex, subunit Delta 1 607246 W09G10.4B 65 apd-3 (apt-5)f R: Emb Let Lva Dpy mocha
AP3M1 AP-3 adaptor complex, subunit Mu1 610366 F53H8.1 80 apm-3 (apt-7)f M: Glo; R: Emb Let Lva Dpy
fat content reduced
AP3M2 AP-3 adaptor complex, subunit Mu2 F53H8.1 79 apm-3 (apt-7)f M: Glo; R: Emb Let Lva Dpy
fat content reduced
AP3S1 AP-3 adaptor complex, subunit Sigma 1 601507 Y48G8AL.14 86 aps-3 (apt-8)f R: Emb Let Lva Dpy maternal sterile
AP3S2 AP-3 adaptor complex, subunit Sigma 2 602416 Y48G8AL.14 88 aps-3 (apt-8)f R: Emb Let Lva Dpy maternal sterile
ARL8B ADP-ribosylation factor-like 8B Y57G11C.13 95 arl-8 R: Emb Let
ARSD Arylsulfatase D 300002 Arylsulfatase
familyc
57
ASAHL N-acylsphingosine amidohydrolase
(acid ceramidase)-like
607469 Y55D5A.3 29 R: none observed
ATP6AP1 ATPase, H+ transporting, lysosomal
accessory protein 1
300197 Y55H10A.1 30 vha-19 M: Let or Ste; R: Ste Sck
ATP6AP2 ATPase, H+ transporting, lysosomal
accessory protein 2
300556 R03E1.2 23 R: Lva Emb Let Unc Lvl
ATP6V0A1 ATPase, H+ transporting, lysosomal
V0 subunit a isoform 1
192130 ZK637.8f 57 unc-32 M: Unc; R: Ste Pvl Sck
Emb Let Unc Gro
ATP6V0A2 ATPase, H+ transporting, lysosomal
V0 subunit a isoform 2
ZK637.8 47 unc-32 M: Unc; R: Ste Pvl Sck
Emb Let Unc Gro
ATP6V0B ATPase, H+ transporting,
lysosomal 21 kDa, V0 subunit b
603717 T01H3.1 64 vha-4 R: Stp Emb Unc Lvl Clr
ATP6V0C ATPase, H+ transporting,
lysosomal 16 kDa, V0 subunit c
108745 R10E11.2 67 vha-2 M: ND; R: Ste Emb Let,
ATP6V0D1 ATPase, H+ transporting,
lysosomal 38 kDa, V0 subunit d1
607028 C30F8.2 75 vha-16f R: Let Lvl Lva Emb maternal sterile
ATP6V0D2 ATPase, H+ transporting,
lysosomal 38 kDa, V0 subunit d2
C30F8.2 81 vha-16f R: Let Lvl Lva Emb maternal sterile
ATP6V0E1 ATPase, H+ transporting,
lysosomal 9 kDa, V0 subunit e1
603931 F49C12.13 71 vha-17 M: ND; R: Ste Sck Emb Lvl Lva
ATP6V0E2 ATPase, H+ transporting, V0 subunit e2 F49C12.13 75 vha-17 M: ND; R: Ste Sck Emb Lvl Lva
ATP6V1A ATPase, H+ transporting,
lysosomal 70 kDa, V1 subunit A
607027 Y49A3A.2 82 vha-13f R: Emb Let Gro Lva Prl
maternal sterile
ATP6V1C1 ATPase, H+ transporting,
lysosomal 42 kDa, V1 subunit C1
603097 Y38F2AL.3A 56 vha-11f R: Ste Emb Let Gro small Sck
Lvl Lva Stp maternal sterile
decreased broodsize
ATP6V1C2 ATPase, H+ transporting,
lysosomal 42 kDa, V1 subunit C2
Y38F2AL.3A 50 vha-11f R: Ste Emb Let Gro small
Sck Lvl Lva Stp maternal sterile
decreased broodsize
ATP6V1D ATPase, H+ transporting,
lysosomal 34 kDa, V1 subunit D
F55H2.2 68 vha-14f R: Emb Let Lva
ATP6V1E1 ATPase, H+ transporting,
lysosomal 31 kDa, V1 subunit E1
108746 C17H12.14 58 vha-8 (pes-6) M: ND; R: Ste Emb Let Gro
Lva decreased broodsize
ATP6V1E2 ATPase, H+ transporting,
lysosomal 31 kDa, V1 subunit E2
C17H12.14 57 vha-8 (pes-6) M: ND; R: Ste Emb Let Gro
Lva decreased broodsize
ATP6V1F ATPase, H+ transporting,
lysosomal 14 kDa, V1 subunit F
607160 ZK970.4 70 vha-9f R: Emb Let Lvl Unc Lva
maternal sterile
ATP6V1G1 ATPase, H+ transporting,
lysosomal 13 kDa, V1 subunit G1
607296 F46F11.5 53 vha-10f R: Emb Lvl Ste Etv
ATP6V1G2 ATPase, H+ transporting,
lysosomal 13 kDa, V1 subunit G2
606853 F46F11.5 35 vha-10f R: Emb Lvl Ste Etv
ATP6V1G3 ATPase, H+ transporting,
lysosomal 13 kDa, V1 subunit G3
F46F11.5 42 vha-10f R: Emb Lvl Ste Etv
ATP6V1H ATPase, H+ transporting,
lysosomal 50/57 kDa, V1 subunit H
608861 T14F9.1 45 vha-15f R: Emb Let Lva Prl Lvl Bli
BLOC1S1 Biogenesis of lysosome-related organelles
complex 1 (BLOC1) subunit 1
601444 T20G5.10 67 R: none observed
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Table 3 (continued)
Human
gene
Protein MIM
number
C. elegans
homologue
% Similarity
to human
gene
Mutant/CGC
namea
RNAi and mutant phenotypesb KO or
spontaneous
mouse mutants
BLOC1S2 Biogenesis of lysosome-related organelles
complex 1 (BLOC1) subunit 2
609768 Y73B6BL.30 62 R: none observed
BLOC1S3 Biogenesis of lysosome-related organelles
complex 1 (BLOC1) subunit 3
609672 Noned
CD222 IGF2R 147280 F23D12.2 34 R: none observed
CD63 Lysosomal membrane
glycoprotein CD63/GP53
155740 T23D8.2 34 tsp-7 R: none observed
T14G10.6 27 tsp-12 M, R: none observed
CD68 CD68 153634 Lectin familyc
CLCN3 Chloride channel 600580 C07H4.2 45 clh-5 M: Let, Ste; R: mild endocytosis
defect (compared to cup-5)
clcn3
CLCN6 Chloride channel 602726 R07B7.1 60 clh-6 M: ND; R: none observed clcn6
CNO Cappuccino, homologue
of mouse, BLOC1 subunit
605695 None cappuccino
CPVL Carboxypeptidase, vitellogenic-like 609780 Serine
carboxypeptidase
familyc
54
CTBS Chitobiase 600873 T01C4.1 25 R: none observed
CTSB Cathepsin B 116810 F57F5.1e 52 ? M: ND; R: Emb Unc Lva ctsb
W07B8.5 48 cpr-5f R: none observed
C52E4.1 51 cpr-1 (gcp-1) M: ND; R: none observed
F44C4.3 36 cpr-4 M: ND; R: none observed
C25B8.3 49 cpr-6 M, R: none observed
W07B8.4 49 R: none observed
W07B8.1 43 R: none observed
F36D3.9 45 cpr-2f R: none observed
T10H4.12 45 cpr-3 M: ND: R: Emb Let
F32H5.1 40 R: Gro
Y65B4A.2 42 R: None observed
CTSF Cathepsin F 603539 F41E6.6 49 tag-196 M: mild Unc Egl;
R: none observed
ctsf
R09F10.1 35 R: none observed
R07E3.1 35 ? M: ND; R: none observed
CTSH Cathepsin H 116820 K02E7.10 37 R: none observed
C50F4.3 30 tag-329 M: Gro Lvl decreased broodsize;
R: none observed
Y113G7B.15 33 R: none observed
CTSL Cathepsin L 116880 T03E6.7 49 cpl-1 M: ND; R: Emb Let Gro Unc ctsl
Y51A2D.8 32 R: none observed
CTSL2 Cathepsin L2 603308 Y71H2AR.2 38 R: none observed
CTSS Cathepsin S 116845 Y40H7A.10 33 ? M: ND; R: none observed
F15D4.4 30 R: none observed
CTSZ Cathepsin Z 603169 F32B5.8 55 cpz-1 M: ND; R: Emb Let Lva Bmd
Mlt maternal sterile
M04G12.2 50 cpz-2 M: ND, R: none observed
DNASE2 Deoxyribonuclease II, lysosomal 126350 F09G8.2 34 tag-198 M, R: none observed
ENTPD4 Ectonucleoside triphosphate diphosphorylase 4 607577 C33H5.14c 32 ntp-1f R: none observed
GGH Gamma-glutamyl hydrolase 601509 None
HLA-DMA Major histocompatibility complex,
class II, DM alpha
142855 None
HLA-DMB Major histocompatibility complex,
class II, DM beta
142856 None
HYAL2 Hyaluronidase 2 603551 T22C8.2 31 R: none observed
IFI30 Interferon-inducible protein 30 604664 F37H8.5 51 R: none observed
C02D5.2 50 R: none observed
LAMP1 Lysosomal-associated membrane protein 1 153330 C05D9.2 36 lmp-2f R: none observed
LAMP3 Lysosomal-associated membrane protein 3 605883 Lectin familyc
LAPTM4A Lysosomal-associated protein
transmembrane 4A
C05E11.3 46 R: none observed
F23D12.1 50 R: none observed
LAPTM4B Lysosomal-associated protein transmembrane 4B C05E11.3 45 R: none observed
LAPTM5 Lys.-assoc. multispanning membrane protein-5 601476 C05E11.3 28 R: none observed
LGMN/
PRSC1
Legumain; hydrolysis of asparaginyl bonds 602620 T28H10.3 42 R: Emb Let
LRP2 Glycoprotein 330 600073 F29D11.1 30 lrp-1 M: Lvl Mlt; R: Gro Prl Mlt Unc
Lvl Bmd Dpy Lva Rup Mig
LYPLA3 Lysophospholipase 3
(lysosomal phospholipase A2)
609362 M05B5.4 46 R: fat content reduced
MUTED Muted, homologue of mouse, BLOC1 subunit 607289 None muted
NAGPA N-acetylglucosamine-1-phosphodiester
alpha-N-acetylglucosaminidase
607985 EGF-like
domain familyc
OSBP Oxysterol binding protein 167040 Y47D3A.17 64 obr-1f R: Emb Let
PAQR8 Progestin and adipoQ receptor family member VIII 607780 K11C4.2 26 R: none observed
PCYOX1 Prenylcysteine oxidase 1 None
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Human
gene
Protein MIM
number
C. elegans
homologue
% Similarity
to human
gene
Mutant/CGC
namea
RNAi and mutant phenotypesb KO or
spontaneous
mouse mutants
PLDN Pallidin, BLOC-1 subunit 604310 None
PPT2 Palmitoyl-protein thioesterase 2 precursor 603298 F44C4.5 51 ppt-1 M: delayed egg-laying,
abnormal mitochondria;
R: none observed
PRCP Prolylcarboxypeptidase 176785 ZK112.1 41 pcp-1f R: none observed
PRDX6 Peroxiredoxin 6; involved in redox
regulation of the cell
602316 Y38C1AA.11 50 prdx-6f R: ND
PRSS16 Protease, serine 16 (thymus) 607169 K12H4.7A 48 R: none observed
C26B9.5 44 R: none observed
F19C7.2 45 R: none observed
F19C7.4 43 R: none observed
F23B2.11 46 pcp-3f R: none observed
F23B2.12 45 pcp-2 M: ND, R: None observed
RAB7A Ras oncogene family member RAB7A 602298 W03C9.3 86 rab-7 M: ND; R: Emb Let Bmd Dpy
Prl Ced fat content reduced
SCARB2 Lysosomal integral membrane
protein II (CD36L2/LGP85/LIMP II)
602257 Y49E10.20 28 ? M: ND; R: Pvl maternal sterile scarb2
Y76A2B.6 28 ? M: ND; R: none observed
SLC30A2 Solute carrier family 30 member 2,
zinc transporter
609617 T18D3.3 69 ? M: ND, R: none observed
SLC36A1 Solute carrier family 36 member 1 606561 T27A1.5 34 R: RIC
SNAPAP Snapin, SNARE and BLOC-1 component 607007 C02B10.2 51 ? M: ND; R: Emb
SNX1 Sorting nexin 1 601272 C05D9.1 59 snx-1 M: Egl, slightly bloated,
HSN migration defects;
R: None observed
STX7 Syntaxin 7 603217 F36F2.4 58 syn-13 M: none observed; R: Emb Let
STX12 Syntaxin 12 606892 F36F2.4 58 syn-13 M: none observed; R: Emb Let
SYBL1/
VAMP7
Synaptobrevin-like 1 300053 Y69A2AR.6 53 R: none observed
SYT7 Synaptotagmin 7 604146 C08G5.4 62 snt-6 R: none observed
TMEM9 Transmembrane protein 9. Involved in
intracellular transport endosomes
and lysosomes
R12C12.6 55 R: none observed
a ? Deletion mutant, gene name unknown.
b Phenotype abbrevations: Bli: blistered; Bmd: organism morphology abnormal, Ced: cell death abnormal; Clr: clear; Dpy: dumpy; Egl: egg-laying defect; Emb: embryonal lethal;
Etv: embryonic terminal arrest variable emb; Glo: gut ﬂuorescence loss; Gro: slow growth; Lva: larval arrest; Let: lethal; Lvl: larval lethal; Mig: cell migration abnormal; Mlt: molting
defect; Prl: paralyzed; Pvl: protruding vulva; Ric: aldicarb resistant; Rup: exploded through vulva; Sck: sick; Ste: sterile; Stp: sterile progeny; Unc: uncoordinated.
c BLAST hitN1 e-5, but no reciprocal BLAST hits; when given: similarity with highest hit.
d None: Blast hitb1 e-5.
e Due to similarity of cathepsin protein sequences, different homologous pairs are shown.
f Gene name assigned, but no mutant available.
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families, is also represented in the worm.
For each of the 94 worm homologues listed, we have compiled the
available information about their mutant and RNAi knock-down
phenotypes. Mutants for 40 homologues have been identiﬁed, but
only half of them have been characterized phenotypically. Six of these
have no obvious phenotype. Most of the homologues have been
included in genome-wide RNAi knock-down experiments, but for 57
of them no phenotype was observed. The most common phenotype
observed in RNAi knock-down experiments for these genes was
embryonic lethality (Emb: 28 times) followed by lethality (Let: 22
times) and larval arrest (Lva: 15 times). A selection of these
homologues with interesting phenotypes is discussed below.
1.8.1. The C. elegans LRP-2/glycoprotein 330 homologue is essential for
nematode life
LRP2/glycoprotein 330 is a member of the LDL receptor protein (LRP)
family involved in endocytosis. Its mouse, zebraﬁsh and worm homo-
logues play a role in development [80]. The C. elegans homologue of this
protein, lrp-1was shown to be essential for growth and development of
the nematode, as lrp-1 mutants show larval arrest and molting defects
[81].Moreover, homozygous lrp-1mutants also aremoderately dumpy, a
phenotype observed previously in worms with cuticle synthesis deﬁ-
ciencies [82]. Although lrp-1 mutants appeared to have normal cuticle
synthesis, they may have aberrant cuticle renewal. Interestingly, lrp-1
mutants phenocopiedwildtypeworms thatwere starved for cholesterol,
supporting a role for LRP-1 in sterol endocytosis. Recently, a geneticinteractionwas identiﬁedbetween LRP-1 andhgrs-1, which is involved in
sorting of endocytosed proteins [83]. In hgrs-1 mutants, the LRP-1
protein was mislocalized, indicating that hgrs-1 is required for correct
endocytic trafﬁcking of the LRP-1 protein. The phenotype of hgrs-1
mutants resembled that of lrp-1 mutants and wildtype worms starved
for cholesterol. This suggests that other genetic or biochemical inter-
actions may be identiﬁed by isolating mutants with lrp-1-like pheno-
types or through RNAi screens for modiﬁers of the lrp-1 phenotype.
1.8.2. The multifunctional role of cathepsin Z in nematode development
The cathepsin Z protein is a cysteine protease that acts as a
carboxymonopeptidase and is incorporated in the phagosome [84]. The
protein was detected in cells of the immune system and in tumor cells
and was suggested to also play a role in cell adhesion dependent on β2-
integrin [85]. The nematode homologue of this protein, CPZ-1, was
showntobeessential fordevelopment asRNAiknockdownandmutation
of cpz-1 both lead to embryonic or larval lethality in part of the worm
population [86]. Whether this developmental arrest is caused by defec-
tive phagosome functionor cell adhesionorhas another cause remains to
be elucidated. The exact function of CPZ-1 could be further investigated
in cpz-1mutants or worms depleted for CPZ-1 by RNAi knockdown.
1.8.3. A C. elegans chloride channel involved in endocytosis
The chloride channel protein CLC-3 may play a role in the stabi-
lization of membrane potential of intracellular organelles, and also in
transepithelial transport, cell volume regulation, and endocytosis [87].
Interestingly, deletion of the homologous mouse gene, Clc3, causes
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by toxic glutamate concentrations in the synaptic vesicles of neurons
or defective acidiﬁcation in the endosomal or recycling pathways of
these cells [88]. Similar to mammals, C. elegans has multiple chloride
channels, including the ubiquitously expressed CLC-3 homologue,
CLH-5, which seems to be involved in receptor mediated endocytosis,
because clh-5 RNAi caused an endocytosis defect similar to the cup-5
mutant [23]. The relatively mild clh-5 RNAi phenotype could be
explained by chloride channel redundancy.
1.9. Human genes involved in lysosomal functioning without C. elegans
homologues
Eight of the human genes listed in Table 3 have no worm
counterpart based onprotein sequence similarity. Four of them encodeTable 4
C. elegans phenotypes associated with changes in lysosomal function
Mutant or RNAi phenotype Primary gene
associated
with
lysosomal
phenotype
C. elegans
Locus
name
Gene
name
Coelomocyte uptake defect, accumulation
of refractile cell corpses
cup-5 R13A5.
cup-1,
cup-3,
cup-6 –
cup-11
?
cup-2 F25D7.1
cup-4 C02C2.
rme-1 W06H8
rme-6 F49E7.1
rme-8 F18C12
Gut granule biosynthesis defect glo-1
glo-1 R07B1.1
glo-3 ?
glo-4 F07C3.4
pgp-2
(glo-5)
C34G6.
haf-4 W04C9
apt-6 R11A5.
apt-7 F53H8.
vps-16 C05D11
vps-41 F32A6.
Loss of one type of intestinal granule lmp-1 C03B1.1
Vacuolated intestinal cells, egg retention,
reduced aspartic protease activity,
enzyme processing defect?
cad-1 ?
Slow development, premature egg-laying ncr-1 F02E8.6
Dauer-constitutive (Daf-c) phenotype ncr-1;
ncr-2
F09G8.
DNA in intestinal lumen not degraded nuc-1 C07B5.
Major endodeoxyribonuclease reduced N95%
condensed chromatin persists after apoptosis
Accumulation of enlarged lysosomes, paralysis during 1st
larval stage, larval arrest, persistent apoptotic corpses
idi-1 K06H7.
Coiler; very sluggish, moves poorly; slightly Egl slightly
short; defecation defects, abnormal FITC staining;
subviable. Abnormal adult males tails and spicules
unc-101 unc-
101
K11D2.
a Gene symbols in bold are listed in Table 1.subunits of the biogenesis of lysosome-related organelles complex 1
(BLOC1), of which eight subunits have been identiﬁed in mammals
[89]. Theworm has only homologues of one BLOC1 subunit involved in
Hermansky–Pudlak syndrome, DTNBP1, and the BLOC1S1, BLOC1S2,
and SNAPAP subunits, which are not associated with human disease. It
is unclear whether these proteins are part of a conserved BLOC1 core
complex that on its own can play a role in organelle biosynthesis, or
whether they interact with unidentiﬁed partners, or have acquired a
different function. Another gene, PCYOX1, encodes an enzyme involved
in the degradation of prenylcysteines [90]. Although knock-out mice
accumulate prenylcysteines in brain cells, this does not seem to lead to
lysosomal storage, brain pathology or histological features normally
associated with lysosomal storage diseases. It is tempting to speculate
that the accumulating prenylcysteines can be localized in (lysosomal)
membranes without problems until their concentration starts toHuman
homologue
%
Similarity
to human
gene
Function of
(human) protein
MIM
number
References
1 MCOLN1 55 Mucolipin-1 605248 [33]
? [23] PNAS 99:
4355 (2002)
DERL1 65 Misfolded protein
degradation in ER
608813
3 CHRNB1 43 Acetylcholine receptor 100710
.1 EHD1 81 Intracellular sorting 605888 [23]
GAPVD1 52 Rab5-activating protein 6,
endocytosis
[23]
.2 DNAJC13 64 DnaJ (Hsp40) homologue [23]
2 RAB32 66 Ras oncogen family
member RAB32
?
HERC4 43 Hect domain and RLD 4,
ubiquitin ligase
4 ABCB1 66 ATP binding cassette
transporter B1
171050 Mol Biol Cell 18:
995 (2007)
.1 ABCB9 41 ATP binding cassette
transporter B9
605453
1 AP3B1
(HPS2)
56 AP-3 complex
subunit beta-1
603401
1 AP3M1 80 AP-3 complex, subunit
Mu1
610366
.2 VPS16 44 Vacuolar protein
sorting-associated
protein 16 homologue
608550
3 VPS41 51 Vacuolar protein
sorting-associated protein
41 homologue
605485
2 LAMP1 57 Lysosomal-associated
membrane protein
153330 [22]
? Genetics 119: 355
(1988) J Biol Chem
275: 26359 (2000)
NPC1 46 Niemann–Pick C1
protein precursor
257220 [44]
4 NPC1 47 Niemann–Pick C1
protein precursor
257220 [44]
5 DNASE2B 54 Deoxyribonuclease II beta Genetics 129:
79 (1991)
Science 220:
1277 (1983)
9 IDI1 56 isopentenyldiphosphate
isomerase
604055 Mol Gen Genomics
273: 158 (2005)
3 AP1M1 88 AP-1 complex,
subunit Mu1
603535 Genes Dev. 8:
60 (1994)
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interferes with the function of membrane proteins.
1.10. Comparison of phenotypes related to C. elegans loci affecting
lysosomal function
The size, number, appearance or electron density of the gut
granules or other lysosome-related vesicles in coelomocytes has been
used in genetic screens to isolate mutants with putative lysosomal
phenotypes, such as coelomocyte uptake (Cup) and gut granule loss
(Glo). Genetic mapping has led to the identiﬁcation of several genes
involved in these phenotypes, which have been compiled together
with other potential lysosomal phenotypes in Table 4. The loci cup-2,
cup-4, glo-4 and glo-5 were found to encode homologues to DERL1,
CHRNB1, HERC4 and ABCB1, respectively [23,24,91]. In addition, three
existing rmemutants displayed the Cup phenotype [23], whereas ﬁve
known genes were involved in the Glo phenotype [24] (Table 4). These
genes encode proteins with functions in other locations within the
cell. Many of these proteins probably play an important role in the
processes discussed in the introduction: lysosome biogenesis, main-
tenance of endosomal transport and lysosomal enzyme targeting. The
associated phenotypes vary in severity, but are relatively subtle and
more similar to those in Table 1 than to those in Tables 2 and 3.
2. Summary and conclusion
Most of the human genes involved in lysosomal storage disorders
have single C. elegans homologues (Table 1). A few human genes have
more than one worm counterpart and vice versa. The reason for the
existence of multiple worm homologues of SMPD1 and CLN3 is
unclear, although temporal and spatial expression patterns differ for
the asm and cln-3 paralogues [41,74]. The representation of three
human enzyme-encoding gene pairs, HEXA-HEXB, GLA-NAGA and
GALNS-ARSA, by single worm homologues might be considered as an
indication of simpler biochemical pathways in the worm. The worm
GANA-1 homologue combines the GLA and NAGA enzyme activities
into one multifunctional enzyme [92]. Several genes (e.g., 6 HPS and 4
CLN genes) involved in human lysosomal storage disorders have no
worm counterparts, which may in part be associated with the lack of
cell types with specialized lysosome-related cell organelles, such as
melanosomes, in theworm. This may also explainwhy theworm lacks
four subunits of the BLOC1 complex involved in the biogenesis of
lysosome-related organelles (Table 3). Furthermore, due the complex-
ity of the human brain, man may require a larger repertoire of CLN
proteins, some of which have additional roles in synaptic vesicles. In
general, however, the nematode C. elegans has largely the same
number of proteins involved in lysosomal processes as man.
The mutant or RNAi knock-down phenotypes for 147 worm genes
ranged from embryonic lethality via subtle intermediate phenotypes
to none observed (Tables 1–3). Phenotypes of lysosomal storage
disease related worm homologues (Table 1) or lysosomal worm
mutants (Table 4) seem to be more subtle than those of homologues,
which are not yet associated with lysosomal storage disease (Table 3).
Worm models of human lysosomal storage disorders have diverse
phenotypes ranging from seemingly apparent lysosomal nature, such
as the endocytosis defect in cup-5 mutants or lmp-1mutants that have
lost one type of intestinal granule presumed to be pre-lysosomes, to
less directly lysosome-related, such as the disturbed cholesterol
trafﬁcking of the ncr mutants, developmental arrest or decreased life
span or brood size. Speciﬁc phenotypes associated with changes in
lysosomal proteins can also be caused by defects in proteins, which do
not localize to lysosomes, but exert their function in lysosome
biogenesis, maintenance of endosomal transport and lysosomal
protein targeting. Their human homologues might be good candidates
for disorders with lysosomal storage or lysosomal dysfunction without
known cause.Severe phenotypes, such as (embryonic) lethality and larval arrest,
are observed for genes encoding parts of the vacuolar proton pump. The
latter genes play an important role inmultiple processes and organelles.
Their inactivation may lead to pleiotropic effects, having a more severe
impact on theworm.Multiple copies of the vacuolar protonpump genes
in man, however, may provide sufﬁcient redundancy to prevent severe
pleiotropic effects unless multiple genes are hit.
Genetic redundancy or the life span of the worm, which may be too
short for lysosomal storage to occur, could explain the absence of a
mutant and RNAi knock-down phenotype for many nematode homo-
logues. In addition, most of the mutants were tested under standard
laboratory conditions, which are presumed to be ideal, evading any
stress required for themanifestation of a phenotype. Furthermore, even
when a knock-out mutation causes a phenotype, RNAi knockdownwill
not always result in a phenotype [93]. Last but not the least, regular
genome-wide RNAi screens yield a mass of data potentially providing a
starting point for the investigation of any individual gene, but present
the researcher with the risk to overlook certain subtle phenotypes.
Although the Cup and Glo phenotypes are relatively easy to score using
ﬂuorescence microscopy [23,24], these were not scored in the genome-
wide RNAi screens. Determining a difference in number, size or electron
density of the lysosomal vesicles (Lmp-1, Idi phenotypes) however,
requires time-consuming ultrastructural investigations, which are
usually not included in screens. In general, biochemical parameters
(enzyme activity, metabolic measurements) are also not measured.
The identiﬁcation of additional worm mutants by genetic screens
would help to identify new players in the different processes
necessary for normal lysosomal function and potential new candi-
dates for human hereditary disorders. The nature of the mutant,
genetic or RNAi knockdown, also determines the screenability of
modiﬁer genes as well as the penetrance of the phenotype. The
advantage of the most observed worm phenotypes in Table 3,
developmental arrest or lethality in any life stage, is the relative
ease with which genetic screens can be done for modiﬁers of these
robust phenotypes. Although many lysosomal storage diseases affect
the human brain, the corresponding worm models did not display
lysosomal storage or other effects in the well-characterized nervous
system, thereby eliminating one of the advantages of the worm
compared to other model organisms. Whether the worm is a suitable
model organism to investigate lysosomal storage diseases depends for
a large part on the presence of a clear and sufﬁciently penetrant
phenotype. The observation of many subtle lysosomal mutant
phenotypes in the worm, however, suggests that it may not be trivial
to perform screens for new mutants.
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